Nanox.AI vs Riverain Technologies (2026)
Both work on chest and body computed tomography and they answer different questions. Nanox mines scans taken for unrelated reasons, surfacing coronary calcium and vertebral fractures nobody ordered the scan to look for, with a clearance portfolio built over years and a listed parent behind it. Riverain suppresses the vessels so nodules that vasculature was hiding become visible, which changes what the radiologist sees rather than adding a list of what the model found. For a lung programme Riverain is aimed at the actual reason nodules get missed. For a population health programme Nanox is finding disease nobody was looking for, and generating a follow up obligation the health system pays for, which should be priced alongside the licence.
- Its strategy is opportunistic population health, mining scans taken for other reasons to surface findings including vertebral fractures and coronary calcium.
- A deep clearance portfolio built over years across several anatomical findings, with a listed parent whose filings describe the business.
- For a population health programme, finding disease nobody was looking for is the entire proposition.
- Vessel suppression addresses a specific reason nodules are missed rather than adding another findings list.
- Long established thoracic focus means the products have been in clinical use across several generations of scanner and protocol change.
- For a lung nodule programme, changing what the reader sees is a different intervention from flagging what the model found.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Nanox.AI and Riverain Technologies are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Nanox.AI | Riverain Technologies |
|---|---|---|
| Primary category | Radiology & Imaging AI | Radiology & Imaging AI |
| Founded | 2014 | 2000 |
| Headquarters | Neve Ilan, Israel | Dayton, Ohio, United States |
| Website | nanox.vision | riveraintech.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Nanox.AI its top capability grade on FDA and Regulatory Status. Set against Riverain Technologies, Nanox.AI grades higher on FDA and Regulatory Status and Setting and Specialty Coverage. Its thinnest published disclosure sits on Model Supply Chain Disclosure and AI Liability and Recourse. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards Riverain Technologies its top capability grade on AI Centrality. Set against Nanox.AI, Riverain Technologies grades higher on several axes, including AI Centrality, Model and Technology Transparency and Model Supply Chain Disclosure. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose Nanox.AI or Riverain Technologies?
On the axes where the AI Health Index separates them, Nanox.AI grades higher on FDA and Regulatory Status and Setting and Specialty Coverage, and Riverain Technologies grades higher on several axes, including AI Centrality, Model and Technology Transparency and Model Supply Chain Disclosure. Riverain Technologies leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do Nanox.AI and Riverain Technologies differ most?
The widest separation the AI Health Index records between Nanox.AI and Riverain Technologies is on AI Liability and Recourse, where Nanox.AI grades D and Riverain Technologies grades B. That axis sits in the Regulatory and Compliance group, so it should carry the most weight for a buyer whose binding constraint is where regulatory exposure sits and who carries it.
Where do Nanox.AI and Riverain Technologies grade the same?
The AI Health Index grades Nanox.AI and Riverain Technologies the same on several axes, including Autonomy and Oversight Model, AI Safety and PHI Stewardship and HIPAA and BAA Posture. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have Nanox.AI and Riverain Technologies not disclosed?
At the last review, at least one of Nanox.AI and Riverain Technologies published thin or absent detail on Model Supply Chain Disclosure and AI Liability and Recourse. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Opportunistic detection creates a duty to act whose cost falls on the health system rather than the vendor, since surfaced findings generate follow up imaging, patient notification and an incidental finding pathway, and that should be priced alongside the licence. Nanox publishes no health privacy commitment, data governance framework or subgroup analysis for a product designed to run across whole populations. Neither publishes pricing, and neither publishes performance on the scanner mix and protocols a given department actually uses.